Humana limits Spinraza coverage

In a coverage policy note, Humana Inc. (NYSE:HUM) said it considers Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB) to be “medically necessary” to treat spinal muscular atrophy (SMA) only in patients with certain characteristics consistent with the disease's type 1 form.

The policy limits coverage to patients whose symptoms present by six months of age, who are diagnosed with deletion or mutation of survival of motor neuron 1 telomeric (SMN1) and who have no more than two copies of SMN2...